ViiV Healthcare

82 total trials 38 currently recruiting 32 completed

Trial Pipeline

RECRUITING Phase 2

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

NCT07202546
RECRUITING Phase 1

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

NCT07053384
RECRUITING Phase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV

NCT06724640
RECRUITING Phase 3

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805
RECRUITING Phase 1

First Time in Human Study of Long Acting VH4524184 Formulations

NCT06310551
RECRUITING Phase 1

Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

NCT05674656
RECRUITING Phase 1

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

NCT05418868
ACTIVE NOT RECRUITING Phase 1

A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV

NCT06970223
ACTIVE NOT RECRUITING Phase 1

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults

NCT06786520
ACTIVE NOT RECRUITING Phase 2

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

NCT06741397
ACTIVE NOT RECRUITING Phase 1

A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV

NCT06652958
ACTIVE NOT RECRUITING Phase 1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

NCT06012136
ACTIVE NOT RECRUITING Phase 2

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

NCT05996471
ACTIVE NOT RECRUITING Phase 3

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05917509
ACTIVE NOT RECRUITING Phase 3

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

NCT05911360
ACTIVE NOT RECRUITING Phase 3

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

NCT03299049
ACTIVE NOT RECRUITING Phase 3

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

NCT02951052
ACTIVE NOT RECRUITING Phase 3

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
ACTIVE NOT RECRUITING Phase 3

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

NCT02362503
COMPLETED Phase 1

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

NCT07066722
COMPLETED Phase 1

A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants

NCT06368986
COMPLETED Phase 1

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

NCT05393271
COMPLETED Phase 1

Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults

NCT04425902
COMPLETED Phase 1

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

NCT04563845
COMPLETED Phase 1

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

NCT04484337
COMPLETED Phase 1

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

NCT04263142
COMPLETED Phase 3

Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults

NCT03945981
COMPLETED

Real-world Insights of People With Human Immunodeficiency Virus (HIV) Infection

NCT03400293
COMPLETED Phase 3

Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

NCT03016533
COMPLETED Phase 1

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

NCT03078556
COMPLETED Phase 1

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

NCT02738931
COMPLETED Phase 1

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

NCT02666053
COMPLETED Phase 1

Taste Properties of HIV Inhibitor

NCT02608918
COMPLETED Phase 1

Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

NCT02578277
COMPLETED Phase 1

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

NCT02277600
COMPLETED Phase 1

Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.

NCT02206711
COMPLETED Phase 1

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

NCT02185300
COMPLETED Phase 1

A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

NCT02059031
COMPLETED Phase 1

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

NCT02027454
COMPLETED Phase 2

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

NCT01641809
COMPLETED Phase 1

Evaluation of the Bioequivalence of a Combined Formulated Tablet

NCT01622790
COMPLETED Phase 3

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

NCT01568892
COMPLETED Phase 3

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

NCT01449929
COMPLETED Phase 1

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

NCT01366547
COMPLETED Phase 1

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

NCT01382238
COMPLETED Phase 1

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

NCT01031472
COMPLETED Phase 2

A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir

NCT00950859
COMPLETED Phase 2

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

NCT00827112
COMPLETED Phase 3

Expanded Access Program for Maraviroc At Multiple Centers

NCT00426660
COMPLETED Phase 2

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

NCT00040664
COMPLETED Phase 3

A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

NCT00296504

Phase Distribution

PhaseTrial count
Phase 1 61
Phase 2 7
Phase 3 13

Therapeutic Areas

HIV Infections 36
Infection, Human Immunodeficiency Virus 15
Infections, Human Immunodeficiency Virus and Herpesviridae 1
Human Immunodeficiency Virus-1 1
Healthy Subjects 1
HIV Infection 1
HIV 1

What the Pipeline for ViiV Healthcare Shows

According to the ClinicalTrials.gov registry, ViiV Healthcare is linked to 82 US clinical trials across every stage of research activity. Of those, 38 studies are currently recruiting — about 46% of the sponsor's indexed portfolio — and 32 are already marked complete, representing roughly 39% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for ViiV Healthcare reports 13 late-stage studies (Phase 3 and Phase 4 combined) and 68 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for ViiV Healthcare is HIV Infections with 36 linked trials, and 6 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Read our methodology — how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial